Melanocortin Ligands: 30 Years of Structure-Activity Relationship (SAR) Studies

Medicinal Research Reviews

Volumn 24, Issue 3, 2004, Pages 325-356

  Holder, Jerry Ryan ^a   Haskell Luevano, Carrie ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

G protein coupled receptors; Melanocortin receptors; Melanotropin; Obesity; Peptidomimetic; Structure activity relationship

Indexed keywords

AGOUTI PROTEIN; AGOUTI RELATED PROTEIN; ALPHA INTERMEDIN; ARGININE; ATTRACTIN; BETA INTERMEDIN; CORTICOTROPIN; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; GAMMA INTERMEDIN; HISTIDINE; JRH 322 18; JRH 420 12; LIGAND; MELANOCORTIN; MELANOCORTIN RECEPTOR; MELANOCORTIN RECEPTOR AGONIST; MELANOCORTIN RECEPTOR ANTAGONIST; N ACETYL ALPHA INTERMEDIN[4-10]CYCLO[4 NORLEUCINE 5 ASPARTIC ACID 7 [3 (2 NAPHTHYL)ALANINE] 10 LYSINAMIDE]; NITRIC OXIDE; PHENYLALANINE; PROOPIOMELANOCORTIN; SHU 8914; SHU 9005; SYNDECAN; SYNTHETIC PEPTIDE; TRYPTOPHAN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; DRUG CONFORMATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STABILITY; MOLECULAR DYNAMICS; REVIEW; SIGNAL TRANSDUCTION; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

DRUG DESIGN; HUMANS; LIGANDS; MELANOCYTE-STIMULATING HORMONES; PROTEIN BINDING; RECEPTORS, MELANOCORTIN; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 1842841995     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.10064     Document Type: Review

References (183)

1. Mountjoy KG, Robbins LS, Mortrud MT, Cone RD. The cloning of a family of genes that encode the melanocortin receptors. Science 1992;257:1248-1251.
2. Chhajlani V, Wikberg JES. Molecular-cloning and expression of the human melanocyte stimulating hormone receptor cDNA. FEBS Lett 1992;309:417-420.
3. Chhajlani V, Muceniece R, Wikberg JES. Molecular-cloning of a novel human melanocortin receptor. Biochem Biophys Res Commun 1993;195:866-873.
4. Gantz I, Miwa H, Konda Y, Shimoto Y, Tashiro T, Watson SJ, Delvalle J, Yamada T. Molecular-cloning, expression, and gene localization of a 4th melanocortin receptor. J Biol Chem 1993;268:15174-15179.
5. Gantz I, Tashiro T, Barcroft C, Konda Y, Shimoto Y, Miwa H, Glover T, Munzert G, Yamada T. Localization of the genes encoding the melanocortin-2 (adrenocorticotropic hormone) and melanocortin-3 receptors to chromosomes 18P11.2 and 20Q13.2-Q13.3 by fluorescence in situ hybridization. Genomics 1993;18:166-167.
6. Gantz I, Konda Y, Tashiro T, Shimoto Y, Miwa H, Munzert G, Watson SJ, Delvalle J, Yamada T. Molecular-cloning of a novel melanocortin receptor. J Biol Chem 1993;268:8246-8250.
7. Rosellirehfuss L, Mountjoy KG, Robbins LS, Mortrud MT, Low MJ, Tatro JB, Entwistle ML, Simerly RB, Cone RD. Identification of a receptor for gamma-melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system. Proc Natl Acad Sci USA 1993;90:8856-8860.
8. Labbe O, Desarnaud F, Eggerickx D, Vassart G, Parmentier M. Molecular-cloning of a mouse melanocortin-5 receptor gene widely expressed in peripheral-tissues. Biochemistry 1994;33:4543-4549.
9. Cone RD, editor. The melanocortin receptors. New Jersey: The Humana Press, Inc.; 2000.
10. Eberle AN, editor. The melanotropins: Chemistry, physiology, and mechanism of action. Basel: Karger; 1988.
11. Hadley ME, editor. The melanotropic peptides: Source, synthesis, chemistry, secretion and metabolism. Boca Raton, FL: CRC Press; 1989.
12. Cone RD, Lu D, Koppula S, Vage DI, Klungland H, Boston B, Chen W, Orth DN, Pouton C, Kesterson RA. The melanocortin receptors: Agonists, antagonists, and the hormonal control of pigmentation. Recent Prog Horm Res 1996;51:287-317; Discussion 318.
13. Ringholm A, Fredriksson R, Poliakova N, Yan YL, Postlethwait JH, Larhammar D, Schioth HB. One melanocortin 4 and two melanocortin 5 receptors from zebrafish show remarkable conservation in structure and pharmacology. J Neurochem 2002;82:6-18.
14. Pritchard LE, Turnbull AV, White A. Pro-opiomelanocortin processing in the hypothalamus: Impact on melanocortin signalling and obesity. J Endocrinol 2002;172:411-421.
15. Hruby VJ, Wilkes BC, Hadley ME, Alobeidi F, Sawyer TK, Staples DJ, Devaux AE, Dym O, Castrucci AMD, Hintz MF, Riehm JP, Rao KR. Alpha-melanotropin - The minimal active sequence in the frog-skin bioassay. J Med Chem 1987;30:2126-2130.
16. Castrucci AML, Hadley ME, Sawyer TK, Wilkes BC, Al-Obeidi F, Staples DJ, Devaux AE, Dym O, Hintz MF, Riehm JP, Rao KR, Hruby VJ. Alpha-melanotropin - The minimal active sequence in the lizard skin bioassay. Gen Comp Endocrinol 1989;73:157-163.
17. Haskell-Luevano C, Sawyer TK, Hendrata S, North C, Panahinia L, Stum M, Staples DJ, Castrucci AMD, Hadley ME, Hruby VJ. Truncation studies of alpha-melanotropin peptides identify tripeptide analogues exhibiting prolonged agonist bioactivity. Peptides 1996;17:995-1002.
18. Haskell-Luevano C, Holder JR, Monck EK, Bauzo RM. Characterization of melanocortin NDP-MSH agonist peptide fragments at the mouse central and peripheral melanocortin receptors. J Med Chem 2001;44:2247-2252.
19. Lu DS, Willard D, Patel IR, Kadwell S, Overton L, Kost T, Luther M, Chen WB, Woychik RP, Wilkison WO, Cone RD. Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature 1994;371:799-802.
20. Willard DH, Bodnar W, Harris C, Kiefer L, Nichols JS, Blanchard S, Hoffman C, Moyer M, Burkhart W, Weiel J, Luther MA, Wilkison WO, Rocque WJ. Agouti structure and function - Characterization of a potent alpha-melanocyte-stimulating hormone-receptor antagonist. Biochemistry 1995;34:12341-12346.
21. Fong TM, Mao C, MacNeil T, Kalyani R, Smith T, Weinberg D, Tota MR, VanderPloeg LHT. Art (protein product of agouti-related transcript) as an antagonist of MC-3 and MC-4 receptors. Biochem Biophys Res Commun 1997;237:629-631.
22. Graham M, Shutter JR, Sarmiento U, Sarosi I, Stark KL. Overexpression of AGRT leads to obesity in transgenic mice. Nat Genet 1997;17:273-274.
23. Ollmann MM, Wilson BD, Yang YK, Kerns JA, Chen Y, Gantz I, Barsh GS. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 1997;278:135-138.
24. Shutter JR, Graham M, Kinsey AC, Scully S, Luthy R, Stark KL. Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. Genes Dev 1997;11:593-602.
25. Yang YK, Ollmann MM, Wilson BD, Dickinson C, Yamada T, Barsh GS, Gantz I. Effects of recombinant agouti-signaling protein on melanocortin action. Mol Endocrinol 1997;11:274-280.
26. Nagle DL, McGrail SH, Vitale J, Woolf EA, Dussault BJ, Jr., DiRocco L, Holmgren L, Montagno J, Bork P, Huszar D, Fairchild-Huntress V, Ge P, Keilty J, Ebeling C, Baldini L, Gilchrist J, Burn P, Carlson GA, Moore KJ. The mahogany protein is a receptor involved in suppression of obesity. Nature 1999;398:148-152.
27. Gunn TM, Miller KA, He L, Hyman RW, Davis RW, Azarani A, Schlossman SF, Duke-Cohan JS, Barsh GS. The mouse mahogany locus encodes a transmembrane form of human attractin. Nature 1999;398:152-156.
28. Reizes O, Lincecum J, Wang Z, Goldberger O, Huang L, Kaksonen M, Ahima RS, Hinkes MT, Barsh GS, Rauvala H, Bernfield M. Transgenic expression of syndecan-1 uncovers a physiological control of feeding behavior by syndecan-3. Cell 2001;106:105-116.
29. Miller KA, Gunn TM, Carrasquillo MM, Lamoreux ML, Galbraith DB, Barsh GS. Genetic studies of the mouse mutations mahogany and mahoganoid. Genetics 1997;146:1407-1415.
30. He L, Gunn TM, Bouley DM, Lu XY, Watson SJ, Schlossman SF, Duke-Cohan JS, Barsh GS. A biochemical function for attractin in agouti-induced pigmentation and obesity. Nat Genet 2001;27:40-47.
31. Phan LK, Lin F, LeDuc CA, Chung WK, Leibel RL. The mouse mahoganoid coat color mutation disrupts a novel C3HC4 RING domain protein. J Clin Invest 2002;110:1449-1459.
32. Hruby VJ, Krstenansky JL, Cody WL. Recent progress in the rational design of peptide-hormones and neurotransmitters. Annual Reports in Medicinal Chemistry 1984;19:303-312.
33. Tsatmali M, Ancans J, Thody AJ. Melanocyte function and its control by melanocortin peptides. J Histochem Cytochem 2002;50:125-133.
34. Xu X, Thornwall M, Lundin LG, Chhajlani V. Val92Met variant of the melanocyte stimulating hormone receptor gene. Nat Genet 1996;14:384.
35. van der Velden PA, Sandkuijl LA, Bergman W, Pavel S, van Mourik L, Frants RR, Gruis NA. Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet 2001;69:774-779.
36. Valverde P, Healy E, Sikkink S, Haldane F, Thody AJ, Carothers A, Jackson IJ, Rees JL. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet 1996;5:1663-1666.
37. Schioth HB, Phillips SR, Rudzish R, Birch-Machin MA, Wikberg JE, Rees JL. Loss of function mutations of the human melanocortin 1 receptor are common and are associated with red hair. Biochem Biophys Res Commun 1999;260:488-491.
38. Scott MC, Wakamatsu K, Ito S, Kadekaro AL, Kobayashi N, Groden J, Kavanagh R, Takakuwa T, Virador V, Hearing VJ, Abdel-Malek ZA. Human melanocortin 1 receptor variants, receptor function and melanocyte response to UV radiation. J Cell Sci 2002;115:2349-2355.
39. Stockfleth E, Sterry W. New treatment modalities for basal cell carcinoma. Recent Results Cancer Res 2002;160:259-268.
40. Stander S, Bohm M, Brzoska T, Zimmer KP, Luger T, Metze D. Expression of melanocortin-1 receptor in normal, malformed and neoplastic skin glands and hair follicles. Exp Dermatol 2002;11:42-51.
41. Ha T, Rees JL. Melanocortin 1 receptor: What's red got to do with it? J Am Acad Dermatol 2001;45:961-964.
42. Abdel-Malek ZA. Melanocortin receptors: Their functions and regulation by physiological agonists and antagonists. Cell Mol Life Sci 2001;58:434-441.
43. Luger TA, Brzoska T, Scholzen TE, Kalden DH, Sunderkotter C, Armstrong C, Ansel J. The role of alpha-MSH as a modulator of cutaneous inflammation. Ann NY Acad Sci 2000;917:232-238.
44. Ichiyama T, Sato S, Okada K, Catania A, Lipton JM. The neuroimmunomodulatory peptide alpha-MSH. Ann NY Acad Sci 2000;917:221-226.
45. Bohm M, Luger TA. The role of melanocortins in skin homeostasis. Horm Res 2000;54:287-293.
46. Hassoun HT, Zou L, Moore FA, Kozar RA, Weisbrodt NW, Kone BC. Alpha-melanocyte-stimulating hormone protects against mesenteric ischemia-reperfusion injury. Am J Physiol Gastrointest Liver Physiol 2002;282:G1059-G1068.
47. Gibbs P, Brady BM, Robinson WA. The genes and genetics of malignant melanoma. J Cutan Med Surg 2002;6:229-235.
48. Schaffer JV, Bolognia JL. The melanocortin-1 receptor: Red hair and beyond. Arch Dermatol 2001;137:1477-1485.
49. Schioth HB. The physiological role of melanocortin receptors. Vitam Horm 2001;63:195-232.
50. Bohm M, Schiller M, Stander S, Seltmann H, Li Z, Brzoska T, Metze D, Schioth HB, Skottner A, Seiffert K, Zouboulis CC, Luger TA. Evidence for expression of melanocortin-1 receptor in human sebocytes in vitro and in situ. J Invest Dermatol 2002;118:533-539.
51. Herpin TF, Yu G, Carlson KE, Morton GC, Wu X, Kang L, Tuerdi H, Khanna A, Tokarski JS, Lawrence RM, Macor JE. Discovery of tyrosine-based potent and selective melanocortin-1 receptor small-molecule agonists with anti-inflammatory properties. J Med Chem 2003;46:1123-1126.
52. Hruby VJ, Han G. The molecular pharmacology of alpha-melanocyte stimulating hormone. In: Cone RD, editor. The melanocortin receptors. Totowa, New Jersey: The Humana Press, Inc.; 2000. pp 239-261.
53. Halkerston ID. Cyclic AMP and adrenocortical function. Adv Cyclic Nucleotide Res 1975;6:99-136.
54. Boston BA, Cone RD. Characterization of melanocortin receptor subtype expression in murine adipose tissues and in the 3T3-11 cell line. Endocrinology 1996;137:2043-2050.
55. Grunfeld C, Hagman J, Sabin EA, Buckley DI, Jones DS, Ramachandran J. Characterization of adrenocorticotropin receptors that appear when 3T3-11 cells differentiate into adipocytes. Endocrinology 1985;116:113-117.
56. Slominski A, Ermak G, Mihm M. ACTH receptor, Cyp11A1, Cyp17 and Cyp21A2 genes are expressed in skin. J Clin Endocrinol Metab 1996;81:2746-2749.
57. Low MJ, Simerly RB, Cone RD. Receptors for the melanocortin peptides in the central nervous system. Curr Opin Endocrinol Diabetes 1994;1:1068-1097.
58. Chen AS, Marsh DJ, Trumbauer ME, Frazier EG, Guan XM, Yu H, Rosenblum CI, Vongs A, Feng Y, Cao LH, Metzger JM, Strack AM, Camacho RE, Mellin TN, Nunes CN, Min W, Fisher J, Gopal-Truter S, MacIntyre DE, Chen HY, Van der Ploeg LHT. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat Genet 2000;26:97-102.
59. Butler AA, Kesterson RA, Khong K, Cullen MJ, Pelleymounter MA, Dekoning J, Baetscher M, Cone RD. A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology 2000;141:3518-3521.
60. Lee YS, Poh LKS, Loke KY. A novel melanocortin 3 receptor gene (MC3R) mutation associated with severe obesity. J Clin Endocrinol Metab 2002;87:1423-1426.
61. Mountjoy KG, Mortrud MT, Low MJ, Simerly RB, Cone RD. Localization of the melanocortin-4 receptor (MC4R) in neuroendocrine and autonomic control-circuits in the brain. Mol Endocrinol 1994;8:1298-1308.
62. Gantz I, Konda Y, Tashiro T, Shimoto Y, Munzert G, Miwa H, Delvalle J, Yamada T. Molecular-cloning and expression of a novel melanocortin receptor present in the brain and gut. Gastroenterology 1993;104:A826.
63. Van der Ploeg LH, Martin WJ, Howard AD, Nargund RP, Austin CP, Guan X, Drisko J, Cashen D, Sebhat I, Patchett AA, Figueroa DJ, DiLella AG, Connolly BM, Weinberg DH, Tan CP, Palyha OC, Pong SS, MacNeil T, Rosenblum C, Vongs A, Tang R, Yu H, Sailer AW, Fong TM, Huang C, Tota MR, Chang RS, Stearns R, Tamvakopoulos C, Christ G, Drazen DL, Spar BD, Nelson RJ, MacIntyre DE. A role for the melanocortin 4 receptor in sexual function. Proc Natl Acad Sci USA 2002;99:11381-11386.
64. Huszar D, Lynch CA, FairchildHuntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD, Smith FJ, Campfield LA, Burn P, Lee F. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997;88:131-141.
65. Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 1997;385:165-168.
66. Bultman SJ, Michaud EJ, Woychick RP. Molecular characterization of the mouse agouti locus. Cell 1992;71:1195-1204.
67. Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gruters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998;19:155-157.
68. Yeo GSH, Farooqi IS, Aminian S, Halsall DJ, Stanhope RC, O'Rahilly S. A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat Genet 1998;20:111-112.
69. Hinney A, Remschmidt H, Hebebrand J. Candidate gene polymorphisms in eating disorders. Eur J Pharmacol 2000;410:147-159.
70. Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, Froguel P. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest 2000;106:253-262.
71. Lubrano-Berthelier C, Clement K, Le Stunff C, Dubern B, Froguel P, Bougneres P, Vaisse C. Functional characterization of obesity associated MC4R mutations. Obes Res 2001;9:53S.
72. Hoogduijn MJ, McGurk S, Smit NP, Nibbering PH, Ancans J, van der Laarse A, Thody AJ. Ligand-dependent activation of the melanocortin 5 receptor: Camp production and ryanodine receptor-dependent elevations of [Ca(2+)](i). Biochem Biophys Res Commun 2002;290:844-850.
73. Chen WB, Kelly MA, OpitzAraya X, Thomas RE, Low MJ, Cone RD. Exocrine gland dysfunction in MC5R deficient mice: Evidence for coordinated regulation of exocrine gland function by melanocortin peptides. Cell 1997;91:789-798.
74. Sahm UG, Olivier GWJ, Branch SK, Moss SH, Pouton CW. Influence of alpha-MSH terminal amino-acids on binding-affinity and biological-activity in melanoma-cells. Peptides 1994;15:441-446.
75. 7]alpha-MSH. Discovery of a tripeptidyl agonist exhibiting sustained bioactivity. Ann NY Acad Sci 1993;680:597-599.
76. Haskell-Luevano C, Cone RD, Monck EK, Wan YP. Structure-activity studies of the melanocortin-4 receptor by in vitro mutagenesis: Identification of agouti-related protein (AGRP), melanocortin agonist and synthetic peptide antagonist interaction determinants. Biochemistry 2001;40:6164-6179.
77. Shizume K, Lerner AB, Fitzpatrick TB. In vitro bioassay for the melanocyte stimulating hormone. Endocrinology 1954;54:533-560.
78. Wright RM, Lerner AB. On the movement of pigment granules in frog melanocytes. Endocrinology 1960;66:599-609.
79. Haskell-Luevano C, Hendrata S, North C, Sawyer TK, Hadley ME, Hruby VJ, Dickinson C, Gantz I. Discovery of prototype peptidomimetic agonists at the human melanocortin receptors MC1R and MC4R. J Med Chem 1997;40:2133-2139.
80. Yang YK, Fong TM, Dickinson CJ, Mao C, Li JY, Tota MR, Mosley R, Van Der Ploeg LH, Gantz I. Molecular determinants of ligand binding to the human melanocortin-4 receptor. Biochemistry 2000;39:14900-14911.
81. Hruby VJ, Sharma SD, Toth K, Jaw JY, al-Obeidi F, Sawyer TK, Hadley ME. Design, synthesis, and conformation of superpotent and prolonged acting melanotropins. Ann NY Acad Sci 1993;680:51-63.
82. Sahm UG, Olivier GWJ, Branch SK, Moss SH, Pouton CW. Synthesis and biological evaluation of alpha-MSH analogs substituted with alanine. Peptides 1994;15:1297-1302.
83. Grieco P, Balse-Srinivasan P, Han G, Weinberg D, MacNeil T, Van der Ploeg LHT, Hruby VJ. Synthesis and biological evaluation on hMC(3), hMC(4) and hMC(5) receptors of gamma-MSH analogs substituted with L-alanine. J Pept Res 2002;59:203-210.
84. 2 at the mouse melanocortin receptors: Part 1 modification at the His position. J Med Chem 2002;45:2801-2810.
85. Bednarek MA, Silva MV, Arison B, MacNeil T, Kalyani RN, Huang RRC, Weinberg DH. Structure-function studies on the cyclic peptide MTII, lactam derivative of alpha-melanotropin. Peptides 1999;20:401-409.
86. Kavarana MJ, Trivedi D, Cai M, Ying J, Hammer M, Cabello C, Grieco P, Han G, Hruby VJ. Novel cyclic templates of alpha-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors. J Med Chem 2002;45:2644-2650.
87. 2 at the mouse melanocortin receptors: Part 2 modification at the Phe position. J Med Chem 2002;45:3073-3081.
88. 7] melanocyte stimulating hormone with the human melanocortin-1 receptor. J Biol Chem 1997; 272:23000-23010.
89. Lu D, Haskell-Luevano C, Väge DI, Cone RD. Functional variants of the MSH receptor (MC1R), agouti, and their effects on mammalian pigmentation. In: Spiegel AM, editor. G-proteins, receptors, and disease. New Jersey: The Humana Press, Inc.; 1997. pp 231-259.
90. Lu D, Väge DI, Cone RD. A ligand-mimetic model for constitutive activation of the melanocortin-1 receptor. Mol Endocrinol 1998;12:592-604.
91. Haskell-Luevano C, Sawyer TK, Trumpp-Kallmeyer S, Bikker JA, Humblet C, Gantz I, Hruby VJ. Three-dimensional molecular models of the hMC1R melanocortin receptor: Complexes with melanotropin peptide agonists. Drug Des Discov 1996;14:197-211.
92. 2 at the mouse melanocortin receptors. Part 3: Modifications at the Arg position. Peptides 2003;24:73-82.
93. 2 at the human melanocortin-1 and -4 receptors: Arginine substitution. Bioorg Med Chem Lett 2002;12:2407-2410.
94. Bondebjerg J, Xiang Z, Bauzo RM, Haskell-Luevano C, Meldal M. A solid-phase approach to mouse melanocortin receptor agonists derived from a novel thioether cyclized peptidomimetic scaffold. J Am Chem Soc 2002;124:11046-11055.
95. Haskell-Luevano C, Rosenquist A, Souers A, Khong KC, Ellman JA, Cone RD. Compounds that activate the mouse melanocortin-1 receptor identified by screening a small molecule library based upon the beta-turn. J Med Chem 1999;42:4380-4387.
96. Sebhat IK, Martin WJ, Ye Z, Barakat K, Mosley RT, Johnston DB, Bakshi R, Palucki B, Weinberg DH, MacNeil T, Kalyani RN, Tang R, Stearns RA, Miller RR, Tamvakopoulos C, Strack AM, McGowan E, Cashen DE, Drisko JE, Hom GJ, Howard AD, MacIntyre DE, van der Ploeg LH, Patchett AA, Nargund RP. Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium-3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl) -2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist. J Med Chem 2002;45:4589-4593.
97. Mutulis F, Mutule H, Lapins M, Wikberg JES. Reductive amination products containing naphthalene and indole moieties bind to melanocortin receptors. Bioorg Med Chem Lett 2002;12:1035-1038.
98. Mutulis F, Mutule H, Wikberg JES. N-alkylaminoacids and their derivatives interact with melanocortin receptors. Bioorg Med Chem Lett 2002;12:1039-1042.
99. Pan K, Scott MK, Lee DH, Fitzpatrick LJ, Crooke JJ, Rivero RA, Rosenthal DI, Vaidya AH, Zhao B, Reitz AB. 2,3-diaryl-5-anilino[1,2,4]thiadiazoles as melanocortin MC4 receptor agonists and their effects on feeding behavior in rats. Bioorg Med Chem 2003;11:185-192.
100. Arasasingham PN, Fotsch C, Ouyang X, Norman MH, Kelly MG, Stark KL, Karbon B, Hale C, Baumgartner JW, Zambrano M, Cheetham J, Tamayo NA. Structure-activity relationship of (1-aryl-2-piperazinylethyl)piperazines: Antagonists for the agrp/melanocortin receptor binding. J Med Chem 2003;46:9-11.
101. 2 at the mouse melanocortin receptors: Part 4 modification at the Trp position. J Med Chem 2002;45:5736-5744.
102. Hruby VJ, Sharma SD, Collins N, Matsunaga TO, Russel KC. Applications of synthetic peptides. In: Grant GA, editor. Synthetic peptides: A user's guide. New York: W.H. Freeman; 1992. pp 259-345.
103. Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, Hadley ME. 4-Norleucine, 7-D-Phenylalanine-alpha-melanocyte-stimulating hormone-A highly potent alpha-melanotropin with ultra-long biological-activity. Proc Natl Acad Sci USA 1980;77:5754-5758.
104. Castrucci AML, Hadley ME, Yorulmazoglu EI, Wilkes BC, Sawyer TK, Hruby VJ. Synthesis and studies of melanotropins resistant to enzyme degradation. Yale J Biol Med 1984;57:345-346.
105. Castrucci AM, Hadley ME, Sawyer TK, Hruby VJ. Enzymological studies of melanotropins. Comp Biochem Physiol B 1984;78:519-524.
106. Lerner AB, Lande S, Kulovich S. Biological properties of racemized α-MSH, γ-MSH and ACTH. Excerpta Med Int Congr Ser 1964;83:382-397.
107. Lee TH, Buettnerjanusch V. On mechanism of sodium hydroxide modification of alpha-melanocyte-stimulating hormone. J Biol Chem 1963;238:2012-2015.
108. Lande S, Lerner AB. Racemization of alpha-melanotropin. Biochim Biophys Acta 1971;251:246-253.
109. Engel MH, Sawyer TK, Hadley ME, Hruby VJ. Quantitative determination of amino acid racemization in heat-alkali-treated melanotropins: Implications for peptide hormone structure-function studies. Anal Biochem 1981;116:303-311.
110. Haskell-Luevano C, Miwa H, Dickinson C, Hadley ME, Hruby VJ, Yamada T, Gantz I. Characterizations of the unusual dissociation properties of melanotropin peptides from the melanocortin receptor, hmc 1r. J Med Chem 1996;39:432-435.
111. Grieco P, Balse PM, Weinberg D, MacNeil T, Hruby VJ. D-amino acid scan of gamma-melanocyte-stimulating hormone: Importance of Trp(8) on human MC3 receptor selectivity. J Med Chem 2000;43:4998-5002.
112. Jayawickreme CK, Quillan JM, Graminski GF, Lerner MR. Discovery and structure-function analysis of alpha-melanocyte-stimulating hormone antagonists. J Biol Chem 1994;269:29846-29854.
113. Sawyer TK, Staples DJ, Castrucci AM, Hadley ME, al-Obeidi FA, Cody WL, Hruby VJ. Alpha-melanocyte stimulating hormone message and inhibitory sequences: Comparative structure-activity studies on melanocytes. Peptides 1990;11:351-357.
114. Al-Obeidi F, Hruby VJ, Hadley ME, Sawyer TK, Castrucci AM. Design, synthesis, and biological activities of a potent and selective alpha-melanotropin antagonist. Int J Pept Protein Res 1990;35:228-234.
115. Sawyer TK, Staples DJ, de Lauro Castrucci AM, Hadley ME. Discovery and structure-activity relationships of novel alpha-melanocyte-stimulating hormone inhibitors. Pept Res 1989;2:140-146.
116. 2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. J Med Chem 1995;38:3454-3461.
117. Haskell-Luevano C, Lim S, Yuan W, Cone RD, Hruby VJ. Structure activity studies of the melanocortin antagonist SHU9119 modified at the 6, 7, 8, and 9 positions. Peptides 2000;21:49-57.
118. Bednarek MA, MacNeil T, Kalyani RN, Tang R, Van der Ploeg LH, Weinberg DH. Selective, high affinity peptide antagonists of alpha-melanotropin action at human melanocortin receptor 4: Their synthesis and biological evaluation in vitro. J Med Chem 2001;44:3665-3672.
119. Grieco P, Han GX, Weinberg D, MacNeil T, Van der Ploeg LHT, Hruby VJ. Design and synthesis of highly potent and selective melanotropin analogues of SHU9119 modified at position 6. Biochem Biophys Res Commun 2002;292:1075-1080.
120. Benoit SC, Schwartz MW, Lachey JL, Hagan MM, Rushing PA, Blake KA, Yagaloff KA, Kurylko G, Franco L, Danhoo W, Seeley RJ. A novel selective melanocortin-4 receptor agonist reduces food intake in rats and mice without producing aversive consequences. J Neurosci 2000;20:3442-3448.
121. Skuladottir GV, Jonsson L, Skarphedinsson JO, Mutulis F, Muceniece R, Raine A, Mutule I, Helgason J, Prusis P, Wikberg JES, Schioth HB. Long term orexigenic effect of a novel melanocortin 4 receptor selective antagonist. Br J Pharmacol 1999;126:27-34.
122. Schioth HB, Muceniece R, Mutulis F, Prusis P, Lindeberg G, Sharma SD, Hruby VJ, Wikberg JES. Selectivity of cyclic [DNa17] and [DPhe7] substituted MSH analogues for the melanocortin receptor subtypes. Peptides 1997;18:1009-1013.
123. Schioth HB, Mutulis F, Muceniece R, Prusis P, Wikberg JE. Discovery of novel melanocortin 4 receptor selective MSH analogues. Br J Pharmacol 1998;124:75-82.
124. Yang Y, Chen M, Lai Y, Gantz I, Georgeson KE, Harmon CM. Molecular determinants of human melanocortin-4 receptor responsible for antagonist SHU9119 selective activity. J Biol Chem 2002;277:20328-20335.
125. Hruby VJ, Li G, Haskell-Luevano C, Shenderovich M. Design of peptides, proteins, and peptidomimetics in chi space. Biopolymers 1997;43:219-266.
126. Goodman M, Ro S. Peptidomimetics for drug design. In: Wolff ME, editor. Burger's medicinal chemistry and drug discovery. New York: Wiley; 1995. pp 803-861.
127. Bednarek MA, Macneil T, Kalyani RN, Tang R, Van der Ploeg LHT, Weinberg DH. Analogs of MTI1, lactam derivatives of alpha-melanotropin, modified at the N-terminus, and their selectivity at human melanocortin receptors 3, 4, and 5. Biochem Biophys Res Commun 1999;261:209-213.
128. Grieco P, Lavecchia A, Cai M, Trivedi D, Weinberg D, MacNeil T, Vander Ploeg LH, Hruby VJ. Structure-activity studies of the melanocortin peptides: Discovery of potent and selective affinity antagonists for the hMC3 and hMC4 receptors. J Med Chem 2002;45:5287-5294.
129. Danho W, Swistok J, Cheung A, Chu X-J, Wang Y, Chen L, Bartkovitz D, Gore V, Qi L, Fry D, Greeley D, Sun H, Guenot J, Franco L, Kurylko G, Rumennik L, Yagaloff K. Highly selective cyclic peptides for human melanocortin-4 receptor: Design, synthesis, bioactive conformation, and pharmacological evaluation as an anti-obesity agent. In: Lebl M, Houghten RA, editors. Peptides: The wave of the future: Proceedings of the second international and the seventeenth American peptide symposium. Norwell, MA: Kluwer Academic Publishers; 2001. pp 701-704.
130. Hruby VJ, Grieco P, Balse P, Han G, Weinberg D, McNeil T. New templates for melanocortin analogues. (Abstr Pap Am Chem Soc) 1999;217:231-MEDI.
131. Haskell-Luevano C, Boteju LW, Miwa H, Dickinson C, Gantz I, Yamada T, Hadley ME, Hruby VJ. Topographical modification of melanotropin peptide analogues with beta-methyltryptophan isomers at position 9 leads to differential potencies and prolonged biological activities. J Med Chem 1995;38:4720-4729.
132. Toth G, Russell KC, Landis G, Kramer TH, Fang L, Knapp R, Davis P, Burks TF, Yamamura HI, Hruby VJ. Ring substituted and other conformationally constrained tyrosine analogues of [D-Pen2,D-Pen5]enkephalin with delta opioid receptor selectivity. J Med Chem 1992;35:2384-2391.
133. Qian X, Kover KE, Shenderovich MD, Lou BS, Misicka A, Zalewska T, Horvath R, Davis P, Bilsky EJ, Porreca F, et al. Newly discovered stereochemical requirements in the side-chain conformation of delta opioid agonists for recognizing opioid delta receptors. J Med Chem 1994;37:1746-1757.
134. Mosberg HI, Omnaas JR, Lomize A, Heyl DL, Nordan I, Mousigian C, Davis P, Porreca F. Development of a model for the delta opioid receptor pharmacophore. 2. Conformationally restricted Phe3 replacements in the cyclic delta receptor selective tetrapeptide Tyr-c[DCys-Phe-DPen]OH (JOM-13). J Med Chem 1994;37:4384-4391.
135. Huang ZW, He YB, Raynor K, Tallent M, Reisine T, Goodman M. Main chain and side-chain chiral methylated somatostatin analogs - Syntheses and conformational-analyses. J Am Chem Soc 1992;114:9390-9401.
136. Hruby VJ, Toth G, Gehrig CA, Kao LF, Knapp R, Lui GK, Yamamura HI, Kramer TH, Davis P, Burks TF. Topographically designed analogues of [DPen,DPen5]enkephalin. J Med Chem 1991;34:1823-1830.
137. Hruby VJ. Conformational and topographical considerations in the design of biologically active peptides. Biopolymers 1993;33:1073-1082.
138. Hruby VJ, Al-Obeidi F, Kazmierski W. Emerging approaches in the molecular design of receptor-selective peptide ligands: Conformational, topographical, and dynamic considerations. Biochem J 1990;268:249-262.
139. Haskell-Luevano C, Shenderovich MD, Sharma SD, Nikiforovich GV, Hadley ME, Hruby VJ. Design, synthesis, biology, and conformations of bicyclic alpha-melanotropin analogues. J Med Chem 1995;38:1736-1750.
140. Haskell-Luevano C, Toth K, Boteju L, Job C, Castrucci AM, Hadley ME, Hruby VJ. Beta-methylation of the Phe7 and Trp9 melanotropin side chain pharmacophores affects ligand-receptor interactions and prolonged biological activity. J Med Chem 1997;40:2740-2749.
141. Haskell-Luevano C, Boteju LW, Miwa H, Job C, Al-Obeidi F, Gantz I, Hadley ME, Hruby VJ. Use of topographical modifications of peptides to examine biological mechanisms such as prolongation. In: Kaumaya PTP, Hodges RS, editors. Peptides, chemistry, structure and biology. Kingswinford, England: Mayflower Scientific Ltd.; 1996. pp 831-832.
142. 2 tetrapeptides at the melanocortin receptors. Eur J Pharmacol 2003;462:41-52.
143. 2. (Abstr Pap Am Chem Soc) 2002;223:074-MEDI.
144. Hadley ME, Al-Obeidi F, Hruby VJ, Weinrach JC, Freedberg D, Jiang JW, Stover RS. Biological activities of melanotropic peptide fatty acid conjugates. Pigment Cell Res 1991;4:180-185.
145. Al-Obeidi F, Hruby VJ, Yaghoubi N, Marwan MM, Hadley ME. Synthesis and biological activities of fatty acid conjugates of a cyclic lactam alpha-melanotropin. J Med Chem 1992;35:118-123.
146. Chaturvedi DN, Knittel JJ, Hruby VJ, Castrucci AMD, Hadley ME. Synthesis and biological actions of highly potent and prolonged acting biotin-labeled melanotropins. J Med Chem 1984;27:1406-1410.
147. 7]-alpha-MSH. J Pharm Sci 1985;74:237-240.
148. Sargent DF, Schwyzer R. Membrane lipid phase as catalyst for peptide-receptor interactions. Proc Natl Acad Sci USA 1986;83:5774-5778.
149. Veuillez F, Deshusses J, Buri P. Synthesis and characterization of an acylated di-peptide (Myr-Trp-Leu) with modified transmucosal transport properties. Eur J Pharm Biopharm 1999;48:21-26.
150. Dunphy JT, Linder ME. Signalling functions of protein palmitoylation. Biochim Biophys Acta 1998;1436:245-261.
151. Slepnev VI, Phalente L, Labrousse H, Melik-Nubarov NS, Mayau V, Goud B, Buttin G, Kabanov AV. Fatty acid acylated peroxidase as a model for the study of interactions of hydrophobically-modified proteins with mammalian cells. Bioconjug Chem 1995;6:608-615.
152. Bundgaard H, Moss J. Prodrugs of peptides. Iv: Bioreversible derivatization of the pyroglutamyl group by N-acylation and N-aminomethylation to effect protection against pyroglutamyl aminopeptidase. J Pharm Sci 1989;78:122-126.
153. Bundgaard H, Moss J. Prodrugs of peptides. 6. Bioreversible derivatives of thyrotropin-releasing hormone (TRH) with increased lipophilicity and resistance to cleavage by the TRH-specific serum enzyme. Pharm Res 1990;7:885-892.
154. Schwyzer R. Estimated conformation, orientation, and accumulation of dynorphin a-(1-13)-tridecapeptide on the surface of neutral lipid membranes. Biochemistry 1986;25:4281-4286.
155. 2. At 5th International Melanocortin Meeting. Sunriver, Oregon; August 25-28, 2002.
156. Laster L, Walsh JH. Enzymatic degradation of c-terminal tetrapeptide amide of gastrin by mammalian tissue extracts. Fed Proc 1968;27:1328-1330.
157. Joseph M, Nagaraj R. Interaction of a hydrophobic model peptide and its fatty acid derivative with lipid vesicles. FEBS Lett 1988;238:411-414.
158. Sawyer TK, Hruby VJ, Darman PS, Hadley ME. [half-Cys4,half-Cys10]-alpha-melanocyte-stimulating hormone-A cyclic alpha-melanotropin exhibiting superagonist biological-activity. Proc Natl Acad Sci USA 1982;79:1751-1755.
159. Gudrum VS, Jonsson L, Skarphedinsson JO, Mutulis F, Muceniece R, Raine A, Mutule H, Prusis P, Wikberg JES, Schioth HB. Long term orexigenic effect of a novel melanocortin 4 receptor selective antagonist. Br J Pharmacol 1999;126:27-34.
160. Skuladottir GV, Jonsson L, Skarphedinsson JO, Mutulis F, Muceniece R, Raine A, Mutule I, Helgason J, Prusis P, Wikberg JE, Schioth HB. Long term orexigenic effect of a novel melanocortin 4 receptor selective antagonist. Br J Pharmacol 1999;126:27-34.
161. Schioth HB, Kask A, Mutulis F, Muceniece R, Mutule I, Mandrika I, Wikberg JE. Novel selective melanocortin 4 receptor antagonist induces food intake after peripheral administration. Biochem Biophys Res Commun 2003;301:399-405.
162. Al-Obeidi F, Hruby VJ, Castrucci AM, Hadley ME. Design of potent linear alpha-melanotropin 4-10 analogues modified in positions 5 and 10. J Med Chem 1989;32:174-179.
163. Al-Obeidi F, Castrucci AMD, Hadley ME, Hruby VJ. Potent and prolonged acting cyclic lactam analogs of alpha-melanotropin-design based on molecular-dynamics. J Med Chem 1989;32:2555-2561.
164. 2, on human melanocortin receptors. J Med Chem 1997;40:1738-1748.
165. Bednarek MA, MacNeil T, Tang R, Kalyani RN, Van der Ploeg LH, Weinberg DH. Potent and selective peptide agonists of alpha-melanotropin action at human melanocortin receptor 4: Their synthesis and biological evaluation in vitro. Biochem Biophys Res Commun 2001;286:641-645.
166. Bodi J, Medzihradszky-Schweiger H, Suli-Vargha H. Synthesis and biological activity of cyclic melanotropin peptides. Andreu GE, Andreu D, editors. Leiden: ESCOM Science; 1991. pp 690-691.
167. Hruby VJ, Mosberg HI. Conformational and dynamic considerations in peptide structure-function studies. Peptides 1982;3:329-336.
168. Smith JA, Pease LG. Reverse turns in peptides and proteins. In: Fasman GD, editor. CRC critical reviews in biochemistry. Boca Raton: CRC Pres; 1980.
169. Wilmot CM, Thornton JM. Analysis and prediction of the different types of beta-turns in proteins. J Mol Biol 1988;203:221-232.
170. Rose GD, Gierasch LM, Smith JA. Turns in peptides and proteins. Adv Protein Chem 1985;37:1-109.
171. Prabhu NV, Perkyns JS, Pettitt BM, Hruby VJ. Structure and dynamics of alpha-msh using drism integral equation theory and stochastic dynamics. Biopolymers 1999;50:255-272.
172. Prabhu NV, Perkyns JS, Pettitt BM. Modeling of alpha-msh conformations with implicit solvent. J Pept Res 1999;54:394-407.
173. 2. Biochemistry 1988;27:8181-8188.
174. Al-Obeidi F, O'Connor SD, Job C, Hruby VJ, Pettitt BM. Nmr and quenched molecular dynamics studies of superpotent linear and cyclic alpha-melanotropins. J Pept Res 1998;51:420-431.
175. Lee JH, Lim SK, Huh SH, Lee D, Lee W. Solution structures of the melanocyte-stimulating hormones by two-dimensional nmr spectroscopy and dynamical simulated-annealing calculations. Eur J Biochem 1998;257:31-40.
176. Li SZ, Lee JH, Lee W, Yoon CJ, Baik JH, Lim SK. Type I beta-turn conformation is important for biological activity of the melanocyte-stimulating hormone analogues. Eur J Biochem 1999;265:430-440.
177. Victoria Silva Elipe M, Mosley RT, Bednarek MA, Arison BH. 1h-nmr studies on a potent and selective antagonist at human melanocortin receptor 4 (hMC-4R). Biopolymers 2003;68:512-527.
178. Prachand MS, Dhingra MM, Saran A, Coutinho E, Bodi J, Suli-Vargha H, Medzihardszky K. Comparative conformational studies on cyclic hexapeptides corresponding to message sequence His-Phe-Arg-Trp of alpha-melanotropin by nmr. J Pept Res 1998;51:251-265.
179. Heizmann G, Hildebrand P, Tanner H, Ketterer S, Pansky A, Froidevaux S, Beglinger C, Eberle AN. A combinatorial peptoid library for the identification of novel MSH and GRP/bombesin receptor ligands. J Recept Signal Transduct Res 1999;19:449-466.
180. Martin WJ, McGowan E, Cashen DE, Gantert LT, Drisko JE, Hom GJ, Nargund R, Sebhat I, Howard AD, Van der Ploeg LH, MacIntyre DE. Activation of melanocortin MC(4) receptors increases erectile activity in rats ex copula. Eur J Pharmacol 2002;454:71-79.
181. Thompson DA, Chai BX, Rood HL, Siani MA, Douglas NR, Gantz I, Millhauser GL. Peptoid mimics of agouti related protein. Bioorg Med Chem Lett 2003;13:1409-1413.
182. Joseph CG, Bauzo RM, Xiang Z, Haskell-Luevano C. Urea small molecule agonists on mouse melanocortin receptors. Bioorg Med Chem Lett 2003;13:2079-2082.
183. Kulesza A, Ebetino FH, Mishra RK, Cross-Doersen D, Mazur AW. Synthesis of 2,4,5-trisubstituted tetrahydropyrans as peptidomimetic scaffolds for melanocortin receptor ligands. Org Lett 2003;5:1163-1166.